The data specifically addressing the role of ALK inhibition in LMD is less robust than addressing EGFR inhibition, however, some small studies have been supportive of this approach and have demonstrated efficacy in CNS disease. This evidence concerns the gene EGFR and Langer mesomelic dysplasia.